Merck KGaA, Darmstadt, Germany, partners with Medisafe to help improve medication adherence for Cardiometabolic Patients
- Collaboration to help thousands of patients with chronic conditions to manage their medication intake and improve adherence to treatment
- Merck KGaA, Darmstadt, Germany, continues to strengthen its Primary Care portfolio with additional digital offering
- Brazil, Russia and Mexico among the first countries to benefit from this initiative
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck KGaA, Darmstadt, Germany, patients will have access to a customized version of Medisafe´s mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language.
“This is an extremely important step towards realizing our vision of supporting patients with comprehensive, integrated, value-added services that look beyond medicines to improve treatment outcomes. We are confident that offering such a solution to our patients has the potential to significantly improve medication adherence by giving patients and carers the tools to organize, understand and manage their medications” said Simon Sturge, Chief Operating Officer at Merck KGaA, Darmstadt, Germany, Biopharma business.
Medisafe is a leading medication management and adherence solution in which M Ventures has invested in, which has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. Medisafe has already delivered high rates of adherence across multiple disease areas, and recorded significant improvements - notably, 86% of Stage 2 hypertensive users reduced their risk category to Stage 1 or below.1
This digital solution will complement Merck KGaA´s, Darmstadt, Germany, current offering of Primary Care medicines for cardiometabolic conditions, which includes treatments for type 2 diabetes, thyroid disorders, and cardiovascular diseases. Although many medications are effective in combating chronic diseases, their full benefits are often not realized by the patients. Approximately 50% of patients do not adhere to long-term therapies,2,3 and this percentage is much higher in developing countries.3 A systematic review of anti-diabetic therapies found wide-ranging adherence rates between 36% to 93%.4 This is of great concern when adherence to medication is critical to positive outcomes.
Factors contributing to poor medication adherence are myriad and include those that are related to patients, physicians and healthcare systems, so improving adherence requires a continuous and dynamic process.3 Because of this complex matrix of factors, our knowledge of the underlying causes of poor medication adherence is still very limited. The collaboration with Medisafe offers the possibility to reveal new overall insights into patient behaviors through aggregated and de-identified data collected by Medisafe, which may contribute to improved chronic disease management in the future.
Brazil, Russia and Mexico are the first three countries where patients receiving the company´s primary care medicines will have access to a customized version of Medisafe. Globally, around 60 million patients with chronic conditions are estimated to be treated with Merck KGaA, Darmstadt, Germany medications daily.
1 Medisafe website. Available at: https://medisafe.com/research/ Accessed January 2018
3 World Health Organization. Adherence to Long-Term Therapies. Evidence for Action Geneva: World Health Organization; 2003. Available at: http://whqlibdoc.who.int/publications/2003/9241545992.pdf Accessed January 2017.
4 Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27:1218–1224.
5 Medisafe website. Available at: https://medisafe.com/research/case-study-medisafe-platform-app-increase-medication-adherence/ Accessed January 2018.
Medisafe is a leading medication management and adherence solution in which M Ventures has invested in. It has more than 4 million registered users, 4 billion patient data points and 140,000 apple store reviews with a 4.5-5 rating. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. In addition, Medisafe is HIPPA (Health Insurance Portability and Accountability Act) compliant with the latest ISO 27001 security protection for patient data. In a recent study, its usage resulted in a 20% rise in prescription refills versus control (IMS Study).5 It is, therefore, not surprising that Medisafe has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
MilliporeSigma today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program.